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With the growing need for coronary revascularizations globally, several strategies to restore
blood flow to the heart have been explored. Bypassing the atherosclerotic coronary arter-
ies with autologous grafts, synthetic prostheses, and tissue-engineered vascular grafts
continue to be evaluated in search of a readily available vascular graft with clinically accept-
able outcomes. The development of such a vascular graft including tissue engineering
approaches both in situ and in vitro is herein reviewed, facilitating a detailed comparison
on the role of seeded cells in vascular graft patency.
Keywords: coronary artery bypass grafts, autologous grafts, synthetic prostheses, surface passivation, tissue-
engineered vascular grafts, acellular/decellularized scaffolds, cell sheet tissue engineering, cell seeding
CLINICAL NEED FOR VASCULAR GRAFTS
Of cardiovascular diseases, coronary artery disease (CAD) is the
leading cause of death in the world, accounting for more than
seven million deaths annually (Gaziano et al., 2010). The narrow-
ing of the coronary arteries through the deposition of cholesterol,
lipids, and calcium in a process known as atherosclerosis is the
primary factor in coronary occlusion (Barron et al., 2003). With
increased longevity, urbanization, and lifestyle changes in devel-
oping and transitional countries, the global burden of coronary
heart disease will reach an estimated 82 million disability-adjusted
life years (DALYs, or healthy years of life lost) by 2020 (Mackay
et al., 2004), up from 58 million DALYs in 2001 (Gaziano et al.,
2010).
In cases of advanced atherosclerosis where percutaneous coro-
nary intervention (PCI) is deemed inappropriate for long-term
revascularization, the more invasive coronary artery bypass graft
(CABG) surgery is performed. Suitable bypass grafts are typically
harvested from the patient themselves (autografts), but may also be
obtained from a donor (allografts), a different species (xenografts),
or obtained artificially (Barron et al., 2003).
AUTOLOGOUS GRAFTS
Natural vessel grafts, such as the greater saphenous vein, radial
artery, and internal thoracic artery (ITA) have all been used as
autologous bypass grafts (Dashwood and Tsui, 2013). The saphe-
nous vein is frequently the conduit of choice due to its technical
ease of use, or in cases of multiple grafting procedures or those
patients undergoing repeat surgeries (Dashwood and Tsui, 2013).
Despite the popularity of the saphenous vein bypass graft, it has
shown limited long-term success with patency rates ranging from
57 to 61% at 10 years (Dashwood and Tsui, 2013) due to intimal
and medial hyperplasia (Tatoulis et al., 2004; Sabik et al., 2005).
Hyperplasia typically occurs at the anastomoses in large part due
to the change in hemodynamic environment. The vein graft is
now subject to increased pressures as well as shear and pulsatile
forces associated with arterial blood flow, resulting in a phenotypic
switch of the smooth muscle cells (SMCs) from the contractile to
the synthetic phenotype (Shukla and Jeremy, 2012).
To improve the mechanical properties of arterial vein grafts and
subsequently reduce hyperplasia, researchers have focused on rein-
forcing vein grafts with external support devices. Recently, cobalt–
chromium–nickel–molybdenum–iron alloy fibers were braided to
form an expandable external support (Fluent, VGS-Vascular Graft
Solution, Tel Aviv, Israel) for a vein graft in an ovine model. The
authors observed a twofold decrease in neointimal hyperplasia
from 23.1 mm2 in the control grafts vs. 11.2 mm2 in the supported
grafts. The authors also noted that the graft’s adventitia was incor-
porated into the device’s pores, fixated by a thin layer of lucent
connective tissue (Ben-Gal et al., 2013). Although an improve-
ment in outcome and patency of the supported vein grafts was
observed, the study was terminated at 3 months, which may have
been insufficient to evaluate this medical device for the prevention
of long-term occlusion due to hyperplasia.
External reinforcement around saphenous vein grafts has also
been examined by Zilla and colleagues. In their studies, the authors
devised a constrictive nitinol (nickel–titanium alloy) wire mesh to
limit intimal hyperplasia by controlling the dilatation of the vein
grafts, hence the shear stress, by constricting the diameter of the
blood vessel while concomitantly reducing the wall stress of the
native artery. The authors suggested that the reduction in shear
stress due to the dilatation of the vein graft would induce intimal
hyperplasia and that reducing the diameter of the vein graft would
maintain the shear stress of the native artery. The authors reported
that the vein graft that was constricted by 50% in a baboon model
showed significantly suppressed intimal hyperplasia at both 6 and
12 weeks when compared to the unsupported vein grafts. Addi-
tionally, the authors demonstrated that only in the 50% constricted
vein graft was endothelialization maintained (Zilla et al., 2008).
Although the authors demonstrated some pulse compliance in a
subsequent knitted nitinol wire mesh study, wire breakage and
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a lower degree of surface endothelialization was observed (Zilla
et al., 2011).
Despite the decreased intimal hyperplasia observed with the
supported vein grafts, the wire mesh supports are not biodegrad-
able and thus, introduce the risk of future complications (Vijayan
et al., 2004) should the wire supports fray, break, or undergo
radial narrowing from axial distension (Zilla et al., 2008, 2011).
Vijayan et al. examined a polyglactin biodegradable external sheath
as support for porcine saphenous vein grafts to prevent future
risks from permanent stents. The authors adopted a loose-fitting
macroporous polyglactin stent for bilateral saphenous vein into
common carotid artery interposition grafting in Large White pigs.
At 1 and 6 months, the stented vein grafts showed decreased
neointimal and medial thickening compared to unstented controls
(Vijayan et al., 2004); however, the use of relatively small saphenous
veins for interposition grafts in large arteries may have created
flow conditions not clinically observed in bypass graft surgery
(Zilla et al., 2008).
The radial artery is typically used as a free graft and has shown
patency rates similar to or better than the saphenous vein (Hay-
ward et al., 2010; Webb et al., 2010; Tranbaugh et al., 2012);
however, risk for graft occlusion was higher in small target-vessel
diameter cases (Desai et al., 2007). Moreover, elevated levels of
vasoconstrictors including endothelin-1 and angiotensin II have
been reported during and following the use of the radial artery in
CABG surgery (He and Yang, 1997), necessitating pharmacological
intervention (Chanda et al., 2000; Patel et al., 2012).
The ITA has provided greater long-term patency rates than
the saphenous vein and radial artery due to its resistance to ath-
erosclerosis (Shukla and Jeremy, 2012) and intimal hyperplasia
(Sabik et al., 2005), and is now considered the conduit of choice
for CABG surgery. Despite the increased patency rates resulting
from ITA grafting, several issues remain. Use of the right ITA is
limited due to its lack of proximity to major coronary arterial sites,
rendering its use non-standardized (Bessone et al., 1995). Used as
a free or composite graft, the right ITA has shown early graft occlu-
sion, especially in cases of competitive flow (Kinoshita and Asai,
2011), mild to moderate stenosis (Pevni et al., 2007), and multiple
anastomoses (Manabe et al., 2010).
SYNTHETIC PROSTHESES
Given that in CABG surgery, conduit availability, repeat oper-
ations, and graft failure are very real concerns of the autol-
ogous graft, synthetic materials as vascular grafts have been
explored. Poly(ethylene terephthalate) (PET®, Dacron), expanded
poly(tetrafluoroethylene) (ePTFE, Gore-Tex®), and heparin-
bonded ePTFE (Propaten®) have demonstrated some degree of
success as peripheral vascular grafts for larger vessel diameters due
to high flow rates of blood past the luminal surface (Kapadia et al.,
2008). In smaller diameter vessels (3–6 mm), early graft occlu-
sion is frequently encountered, resulting from thrombogenicity
of the synthetic surface and anastomotic hyperplasia (Chan-Park
et al., 2009). Thrombus formation on the surface of a biomate-
rial is dictated by the Vroman effect of protein adsorption upon
injury following implantation. Multiple factors including blood–
material interactions, the extent of cellular necrosis and inflam-
matory response, the loss of basement membrane structures, and
subsequent provisional matrix formation are all contributing fac-
tors in the cascade of events of wound healing (Anderson, 2001).
In effort to mitigate this cascade of events, much research has
been focused on the passivation of the surface of vascular pros-
theses through the grafting of materials to reduce the electrostatic
and hydrophobic interactions at the blood–biomaterial interface,
and in particular to inhibit platelet adhesion and activation (Jor-
dan and Chaikof, 2007). Natural and synthetic materials including
poly(ethylene glycol) (PEG), dextran, pyrolytic carbon, phospho-
rylcholine (PC), albumin, and elastin-mimetic protein polymers
have been investigated to minimize thermodynamically favored
protein adsorption to the vascular graft surfaces (Jordan and
Chaikof, 2007).
VASCULAR PROSTHESES PASSIVATION
Bureau and colleagues have recently examined non-woven PET
fibers with surface-grafted PEG as potentially non-thrombogenic
surfaces. The authors activated the surface of the PET with
poly(vinyl amine) (PVAm), yielding pendant amine groups that
were conjugated to carboxylic acid terminated PEG oligomers.
The authors reported decreased platelet adhesion and activation
with a 10% PEG solution grafting to the PVAm modified PET
fibers when compared to knitted Dacron; however, the results
were not superior to previously investigated carbon-coated ePTFE
(Dimitrievska et al., 2011). In a prospective randomized multicen-
ter study, Kapfer et al. demonstrated that in an extra-anatomical
anterior tibial artery bypass model, carbon-impregnated ePTFE
prostheses were not significantly better than standard ePTFE grafts
in terms of graft patency or limb salvage (Kapfer et al., 2006). Sim-
ilarly, Wang et al. also used PVAm to develop a surfactant polymer
to coat ePTFE vascular grafts to prevent platelet adhesion and acti-
vation. The authors conjugated dextran to the PVAm backbone,
which mimicked the polysaccharide-rich glycocalyx, generating
a highly hydrated barrier, similar to the PEG-grafted PET fibers,
inhibiting platelet adhesion and activation from both platelet-rich
plasma and whole blood. Despite the promising in vitro results,
the data from the proposed future study in a porcine model were
never reported (Wang et al., 2009).
The highly hydrated surface of erythrocytes is also responsi-
ble for their non-thrombogenicity. The presence of the polar PC
head groups of the lipid bilayer of the cell membrane are elec-
trically neutral at physiologic pH while carrying both positive
and negative charges. The zwitterionic nature of PC, resulting in
the hydrated surface has shown limited protein and cell adhesion
in vitro and thus has been explored as a non-thrombogenic coat-
ing on synthetic prostheses (Jordan and Chaikof, 2007). Yoneyama
et al. demonstrated reduced thrombogenicity in an interposi-
tional carotid rabbit model for up to 5 days with a segmented
poly(etherurethane) (SPU)/2-methacryloyloxyethyl phosphoryl-
choline (MPC) polymer blend coating of Dacron prosthe-
ses (Yoneyama et al., 1998). Similarly, Chaikof and colleagues
deposited a membrane-mimetic film onto the luminal surface
of gelatin-impregnated ePTFE vascular prostheses and demon-
strated reduced platelet adhesion after 1 h in a baboon femoral
arteriovenous shunt model when compared to uncoated ePTFE
grafts. The authors also observed a reduction in fibrinogen adhe-
sion in the membrane-mimetic film coated graft; however, this
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reduction was not significant (Jordan et al., 2006; Jordan and
Chaikof, 2007).
An alternative to the self-assembled phospholipid coating on
MPC is the immobilization of merely the PC head group to the
vascular prosthesis. Chevallier et al. functionalized the surface
of ePTFE grafts through ammonia plasma treatment and then
coupled PC to the resulting surface amino groups. The authors
observed a concomitant decrease in platelet adsorption and
activation and thrombogenicity index in the PC-functionalized
grafts. Moreover, a significant reduction in neutrophil adhe-
sion was observed, indicating a mitigation of the inflammatory
response (Chevallier et al., 2005). In addition to the observed
non-thrombogenicity of the PC, Chen et al. (1997) had previ-
ously demonstrated a reduction in neointimal hyperplasia with a
PC coating of ePTFE grafts in a mongrel dog end-to-side carotid
anastomoses model compared to virgin ePTFE grafts.
Instead of preventing platelet adhesion and activation through
highly hydrophilic surfaces, some researchers have adopted the
approach of controlled protein adsorption to inhibit coagulation.
Albumin induces less platelet adsorption than other plasma pro-
teins such as fibrinogen, which binds to the platelet GP IIb/IIIa
receptor via arginine–glycine–aspartic acid (RGD) sequences
(Zaidi et al., 1996; Jordan and Chaikof, 2007; Srokowski et al.,
2011). Despite albumin’s rapid adsorption to the surface of a syn-
thetic material, more thermodynamically favored proteins replace
albumin on the surface (Andrade and Hlady, 1987). Given the
susceptibility of albumin to be displaced by larger proteins includ-
ing fibrinogen, the promotion of albumin immobilization on
the surface of vascular prostheses has been investigated. Choi
et al. evaluated polylactide coated ePTFE grafts as a media-
tor of protein adsorption. The authors observed a preferential
adsorption of albumin over fibrinogen on the surface of the
coated ePTFE grafts compared to both unmodified and modified
ePTFE grafts. The modified grafts were rendered more hydrophilic
via chemical treatment, yielding an increase in surface energy.
Despite the preferential adsorption of albumin, the polylactide
surfaces induced greater blood cell adhesion than both control
grafts suggesting a thrombogenic nature of the polylactide sur-
face (Choi et al., 2005). In effort to mitigate the thrombogenicity
of a secondary material, albumin was immobilized to the sur-
face of knitted Dacron grafts through glutaraldehyde crosslinking.
In this study, Kottke-Marchant et al. observed reduced platelet
adhesion and aggregation, as well as reduced leukocyte adhesion
with the crosslinked albumin-coated, knitted Dacron grafts when
compared to unmodified Dacron. In addition, the release of fib-
rinopeptide A, an indicator of fibrin formation, was also reduced
in the albumin-coated knitted Dacron (Kottke-Marchant et al.,
1989). Although promising in vitro, no difference was observed
in clinical outcomes between the coated and uncoated grafts in
arterial bypass grafts for aortoiliac disease (Bearn et al., 1993;
Al-Khaffaf and Charlesworth, 1996).
Like albumin, elastin has also inhibited platelet aggrega-
tion (Baumgartner et al., 1976; Barnes and Maclntyre, 1979);
however, the mechanism is not fully understood. Despite
the initial studies of the antagonistic effect of elastin on
platelet aggregation, few studies have evaluated the extracellular
matrix (ECM) protein for passivation of vascular prostheses.
Woodhouse et al. have tested elastin-like peptides (ELPs) as
coatings of vascular graft materials including PET (Mylar™),
poly(tetrafluoroethylene/ethylene) copolymer (Tefzel™), and a
poly(carbonate urethane) (Corethane™). The authors passively
coated all three test materials with a recombinant human elastin
peptide and demonstrated a reduction in platelet activation in all
cases. Moreover, fibrin accretion and thrombus formation on the
surface of a polyurethane catheter was retarded in a New Zealand
white rabbit model (Woodhouse et al., 2004). In a follow-up study,
Woodhouse and colleagues reported platelet adhesion and fib-
rinogen adsorption on Mylar™ coated with three different ELPs.
The authors observed a reduction in fibrinogen adsorption in all
ELP-coated films; however, only the longer polypeptide chains
exhibited decreased platelet adhesion (Srokowski et al., 2011).
In a related study, an elastin-mimetic triblock protein polymer
was evaluated by Chaikof and colleagues as a non-thrombogenic
coating of impregnated ePTFE vascular grafts. They too observed
inhibition of platelet adhesion and fibrin deposition in a baboon
arteriovenous shunt model (Jordan et al., 2007). In addition to the
non-thrombogenicity of ELPs and proteins, Ito et al. examined the
effect of coacervated α-elastin in preventing intimal hyperplasia.
The authors observed a dose dependent decrease in smooth mus-
cle cell proliferation in vitro with crosslinked coacervatedα-elastin,
suggesting a potential reduction of intimal hyperplasia in vivo (Ito
et al., 1998a). The authors repeated the study using tritiated thymi-
dine to monitor cell proliferation and despite evidence suggesting
that tritiated thymidine may result in cell arrest and apoptosis (Hu
et al., 2002), the authors reported increased endothelial cell prolif-
eration at a coacervated α-elastin concentration of 0.1 mg/mL (Ito
et al., 1998b).
BIOACTIVE VASCULAR PROSTHESES
As active members of both anti-coagulant and anti-platelet mecha-
nisms, endothelial cells (ECs) are integral in regulating hemostasis
(Verhamme and Hoylaerts, 2006). Therefore, much research has
been focused on mimicking the anti-thrombogenic features of the
endothelial cell surface. Immobilization of anti-coagulant mole-
cules thrombomodulin and heparin onto the surface of synthetic
materials to directly inhibit thrombus formation has been stud-
ied. Mitigation of thrombus formation can be achieved through a
number of coagulation or fibrinolytic pathways.
The surfaces of ePTFE prostheses have been modified to
minimize pro-coagulation or anti-fibrinolytic mechanisms or
conversely promote anti-coagulation and pro-fibrinolytic path-
ways. Thrombomodulin, an endothelial cell surface glycoprotein,
strongly binds with thrombin forming a complex that inhibits
the pro-coagulant properties of thrombin. Thrombomodulin also
activates the anti-coagulant protease protein C, which further
hinders thrombus formation (Li et al., 2000). Li et al. initially
demonstrated that a soluble recombinant human thrombomod-
ulin dose dependently retarded α-thrombin-induced porcine arte-
rial smooth muscle cell proliferation in vitro (Li et al., 2000).
In a follow-up study, the authors demonstrated a reduction
in neointimal hyperplasia in immobilized recombinant human
thrombomodulin coated ePTFE stent grafts (Wong et al., 2008).
Heparin, a glycosaminoglycan that inhibits both thrombin and
activated factors IX, X, XI, and XII, which are involved in the
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conversion of prothrombin to thrombin (Lin et al., 2004) has
been extensively investigated. In addition to its anti-coagulation
properties, heparin has been shown to reduce smooth muscle cell
proliferation and thus possesses the capability to inhibit intimal
hyperplasia (Clowes and Karnowsky, 1977). Lin et al. demon-
strated the reduction in neointimal hyperplasia at both the prox-
imal and distal anastomoses on heparin-coated ePTFE grafts in
a baboon arteriovenous shunt model, as shown in Figure 1 (Lin
et al., 2004). In a canine carotid artery interposition model, the
end-point covalent attachment of heparin using the Carmeda®
BioActive Surface (CBAS) technology to an expanded polytetra-
fluoroethylene graft compared favorably to a bare ePTFE graft. In
a 2 h acute study, all five heparin-immobilized grafts remained
patent exhibiting strong thromboresistance, while 60% of the
control grafts occluded. In a longer-term study, 13 of 16 con-
trol grafts had occluded as early as 3 days, yet all CBAS–ePTFE
remained patent. Following 180 days in the end-to-end anasto-
moses, seven CBAS–ePTFE grafts had occluded, while the three
control grafts initially patent at 3 days remained patent or par-
tially patent suggesting the heparin-immobilization reduced early
graft thrombosis. Although, there was no statistical loss of heparin
function at 12 weeks, the decreasing trend between weeks 2 and 12
suggests that at 180 days, the increase in occluded CBAS–ePTFE
grafts may have resulted from a loss in heparin bioactivity (Bego-
vac et al., 2003). In an ex vivo study, Heyligers et al. demonstrated a
reduction in fibrinopeptide A on the heparin-immobilized grafts,
suggesting an inhibition of fibrin deposition. Scanning electron
microscopy revealed no platelet aggregation on the surface of
the CBAS–ePTFE grafts confirming the thromboresistant nature
of the heparinized ePTFE grafts (Heyligers et al., 2006). The
promise that the heparin-bonded vascular graft could prevent
early graft thrombosis through anti-coagulation and anti-platelet
mechanisms led to its commercialization (Propaten® W. L. Gore
& Associates, Inc., Flagstaff, AZ, USA) and subsequent use as a
peripheral vascular graft in humans.
In addition to being a part of the anti-coagulation and anti-
platelet mechanisms, ECs also maintain hemostasis by providing
a blood-compatible lining (Mason et al., 1977). In the absence of
an adherent and coherent endothelium along the luminal surface
of a synthetic graft, late stage thrombosis may still occur despite
anti-coagulation therapy. Consequently, research has also focused
on improving endothelial cell growth, retention, and confluency
on the luminal surface of synthetic grafts. Due to electrostatic
and hydrophobic interactions with ePTFE vascular grafts, incom-
plete endothelialization is typically encountered (Lu et al., 2013).
Williams et al. have recently studied the effect of conjugated mouse
laminin type 1 on endothelialization and neovascularization of
ePTFE grafts as interpositional aortic grafts in rats. The presence
of red cells, leukocytes, fibrin, and platelets in the control grafts
suggested a highly thrombogenic surface, while the laminin type
1 conjugated grafts exhibited a complete lining of cells, indicative
of an intact endothelium as shown in Figure 2. The authors also
observed neovascularization in the interstices of the ePTFE grafts
in the laminin-conjugated grafts (Williams et al., 2011).
Alternatively, Kibbe and colleagues mechanically coated the
luminal nodes and fibrils of ePTFE with poly(1,8-octanediol cit-
rate) (POC) and implanted the grafts in a porcine carotid model.
FIGURE 1 | Neointimal hyperplasia at proximal (top) and distal
(bottom) anastomoses. Collagens are blue; elastin is black; others are red.
(A) Anastomoses of untreated expandable poly(tetrafluoroethylene)
(ePTFE) graft (control). (B) Anastomoses of heparin-coated ePTFE graft
(treated). L, Lumen; N, neointima; G, ePTFE graft material
(Verhoeff-Masson stain; original magnification: 40×) (Lin et al., 2004).
FIGURE 2 | Micrographs illustrating the luminal surface of grafts
stained with hematoxylin and eosin [H&E (A,C)] and horseradish
Griffonia simplicifolia (Gs-1) lectin (B,D), which exhibits specificity to
endothelial cells. (A,B) Control graft – note absence of a cellular lining;
(C,D) laminin type 1-treated graft exhibiting a cellular lining that reacted
actively with Gs-1 (Williams et al., 2011). Copyright ©2011 Wiley
Periodicals, Inc.
The authors demonstrated increased endothelial cell growth;
however, confluency was only reached at 10 days. Moreover, the
improved growth rate did not limit neointimal hyperplasia nor
were the authors able to confirm that the neoendothelium was
functional (Kibbe et al., 2010). Hoshi et al. took it a step further
by covalently immobilizing heparin to the shear thinned POC-
coated ePTFE vascular grafts. The authors demonstrated reduced
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whole blood clotting and platelet adhesion of the heparin immobi-
lized POC–ePTFE grafts when compared to both POC–ePTFE and
ePTFE grafts. In addition, the heparin conjugated grafts supported
both endothelial cell and blood outgrowth endothelial cell adhe-
sion as evidenced by expressions of von Willebrand factor (vWf)
and vascular endothelial cadherin (Hoshi et al., 2013). The authors
also claimed that SMCs cultured on the heparin–POC–ePTFE
grafts showed increased expression of α-actin and decreased cell
proliferation, but the smooth muscle α-actin (SMαA) expres-
sion was only examined qualitatively. The cell proliferation data
showed that the heparin conjugated POC–ePTFE grafts resulted in
a decreased SMC proliferation rate only when compared to two-
dimensional cell culture on tissue culture polystyrene (TCPS) and
not when compared to POC–ePTFE grafts (Hoshi et al., 2013).
Although this data does not suggest that intimal hyperplasia may
be reduced due to decreased SMC with the heparin immobilized
POC-coated ePTFE grafts, Hoshi et al. did demonstrate the com-
bined benefit of anti-coagulant therapeutic delivery and improved
endothelialization.
In a study by Lu et al., the authors coated 6 mm diameter ePTFE
vascular grafts with an anti-CD133 antibody-functionalized
heparin/collagen multilayer. Poly(ethyleneimine) (PEI) was elec-
trostatically bound to the surface of the negatively charged ePTFE
graft. Alternating immersion in heparin and collagen solutions
generated a layer-by-layer self-assembled multilayered graft, which
was then crosslinked with glutaraldehyde in the presence of anti-
CD133 to immobilize the antibody to the surface of the vascular
graft. The authors chose to immobilize CD133 to the surface of
the graft as CD133 is a cell surface antigen expressed on endothe-
lial progenitor cells, which induced rapid endothelialization in a
7 day porcine carotid artery transplantation model. In addition to
the in situ endothelialization, the authors reported significantly
decreased platelet adhesion in the heparin/collagen coated ePTFE
grafts. Despite the promise of the reported work, future stud-
ies will need to address two issues – appropriately sized ePTFE
grafts (<6 mm) and longer in vivo studies to ensure no late
stage thrombosis occurs due to a loss of functional endothelium
(Lu et al., 2013).
Flameng and colleagues recently coated stem cell homing fac-
tor (SDF-1α) on the surface of Gelsoft™(Vascutek Ltd., Inchinnan,
Scotland) and Polymaille C (Pérouse Laboratories, Ivry le Temple,
France), which are both knitted polyester vascular grafts pre-
coated with collagen. The authors examined SDF-1α as it acts
as a chemoattractant for hematopoietic stem cells while induc-
ing the recruitment of endothelial progenitor cells. The authors
observed an increase in endothelialization from 27± 4 to 48± 4%
with the SDF-1α coating compared to vascular grafts alone in
an ovine model. Concurrently, they also observed a decrease in
intimal hyperplasia (De Visscher et al., 2012).
DEGRADABLE VASCULAR GRAFTS
Although vascular prostheses are used effectively in large diam-
eter vascular bypass graft surgery, particularly in the treatment
of peripheral artery disease, there still remains no small-diameter
vascular graft with clinically acceptable outcomes. In addition, the
inability of these biostable vascular prostheses to undergo in vivo
remodeling following implantation would preclude their use in
pediatric cardiac patients who would need grafts to grow with
them. Despite this lack of growth potential, the research applied
to the passivation and endothelialization of vascular prostheses
could be employed to vascular grafts that could undergo remod-
eling in vivo. For the vascular graft to integrate with the host’s
tissue, the graft itself must degrade following implantation, but in
a manner adaptive to the needs of the host, ranging from pediatric
to geriatric patients. Engineered degradable vascular grafts cur-
rently under investigation include both synthetic and biologically
derived scaffolds, typically rendered biomimetic through func-
tionalization and then potentially sodded with cells. These avenues
of tissue engineering all seek to produce grafts promoting vascular
cell migration and infiltration, presenting a non-thrombogenic
luminal surface, and providing appropriate viscoelasticity and
mechanical strength, especially during tissue regeneration.
TISSUE ENGINEERING OF VASCULAR GRAFTS IN VIVO
One approach in designing tissue-engineered vascular grafts
(TEVGs) is through the implantation of an “off-the-shelf” acel-
lular vascular scaffold. In vivo tissue engineering of vascular
grafts necessitates the host’s cells to infiltrate and populate a
non-thrombogenic three-dimensional porous matrix, while con-
comitantly preventing blood leakage through the graft. As stated,
the scaffold must also remain compliant to preserve the nec-
essary hemodynamic environment, yet provide sufficient burst
pressure and suture retention strengths. Given the extensive list
of pre-requisites of a tissue-engineered vascular graft, numerous
approaches have been adopted.
Walpoth and colleagues recently evaluated a bilayered
biodegradable electrospun polycaprolactone (PCL) scaffold as a
vascular graft. The authors prepared the bilayered PCL graft by
electrospinning two different concentrations of PCL to obtain a
nanofibrous luminal surface, and a microfibrous adventitial side
(de Valence et al., 2012). The microfibrous matrix was designed
to allow a dense infiltration of the SMCs, while the nanofibrous
structure was designed to allow the ECs to bridge the gaps to
form a confluent monolayer to prevent blood leakage. In a 4-
week bilateral porcine carotid artery model, the authors observed
a marginal improvement in graft patency – 78 versus 67% for the
PCL and ePTFE vascular grafts, respectively. An increase in neoen-
dothelialization from 58 to 86% was also observed in the PCL
grafts. Despite the increase in endothelialization, neointima, and
thrombus formation were not improved with the PCL electrospun
vascular grafts (Mrówczyn´ski et al., 2014). In a long-term follow-
up study, the authors compared the patency of the bilayered PCL
vascular graft against the ePTFE prosthesis in a Sprague-Dawley
rat aorta replacement study. At a median of 16.5 months, the rats
were euthanized, and the grafts were excised and examined. Graft
patency in the PCL grafts was 100%, while only 67% of ePTFE
grafts remained patent. Although, there was a reduction in calci-
fication and a concomitant improvement in cell infiltration and
graft compliance with the PCL grafts when compared to ePTFE
grafts, the PCL graft compliance was markedly less than the native
aorta (Mugnai et al., 2013).
In a progressive study, Wang et al. (2014) examined the effect
of PCL fiber diameter and pore size on arterial regeneration in
a rat abdominal aorta model. All grafts remained patent through
www.frontiersin.org June 2014 | Volume 1 | Article 4 | 5
Knight et al. Tissue engineering strategies for coronary revascularization
28 days, with one thicker-fiber (5–6µm) graft becoming occluded
at 100 days (80% graft patency). Of all patent grafts, the lumi-
nal surface was smooth and free of platelets and thrombi, with a
stable inner diameter suggesting no measurable restenosis. More-
over, significant cell infiltration was observed as early as 7 days in
the thicker-fiber graft with both hematoxylin and eosin (H&E)
and 4′,6-diamidino-2-phenylindole (DAPI) staining when com-
pared to the thinner-fiber (0.7µm) graft. Of the infiltrating cells,
SMαA-positive cells were observed at 7 days around the connective
tissue, but had migrated toward the luminal surface at 14 days. In
addition, two of three explanted grafts exhibited a dense medial
layer of smooth muscle myosin heavy chain (SMMHC)-positive
cells at 28 days suggesting the generation of mature smooth mus-
cle, which contracted in response to vasoconstrictors potassium
chloride (KCl) and adrenaline. Although complete endothelializa-
tion was not yet achieved at 28 days, vWf immunostaining revealed
a coherent layer of ECs along the luminal surface of the graft at
day 100, which underwent acetylcholine-induced relaxation fol-
lowing vasoconstriction. Given the functional smooth muscle and
endothelium, histological staining with H&E, Masson’s trichrome,
and Verhoeff-van Gieson (VVG) confirmed the initiation of vas-
cular remodeling, as neotissue was observed in the lumen with
ECM deposition within the graft. Although the elastin within the
explanted graft did not exhibit the degree of undulation of the
native aorta, the fibers were oriented circumferentially as part of as
sub-endothelial layer. Despite the secretion of collagen and elastin,
the circumferential strength of the explanted grafts mirrored that
of the pre-implanted graft, while the magnitude of the contractile
response of the explanted grafts were far less than the native aorta
indicating little PCL matrix degradation (Wang et al., 2014). Given
that arterial remodeling is expected to be slower in humans com-
pared to rats (Swartz and Andreadis,2013), the stiffer PCL (Young’s
modulus ~ 21 MPa) vascular graft (Wang et al., 2014) could per-
sist further mitigating vascular remodeling, while concomitantly
limiting elastin synthesis (Crapo and Wang, 2010).
To further improve the interaction of PCL with both ECs
and SMCs, recent work has focused on incorporating tripeptides
to direct cell behavior. The cell adhesive motif RGD has been
incorporated into a PCL-functionalized vascular graft. A naph-
thalene conjugated hexapeptide phenylalanine–phenylalanine–
glycine–arginine–glycine–aspartic acid (FFGRGD) self-assembled
on the surface of the hydrophobic PCL yielding pendant RGD
handles, which have previously been shown to provide improved
hydrophilicity, cell attachment, and spreading. In an arteriove-
nous shunt model in female New Zealand White rabbits, Zheng
et al. observed reduced platelet adhesion, improved patency, and
smooth muscle cell infiltration and greater endothelialization
with the RGD-functionalized PCL grafts. Although the authors
reported improved smooth muscle cell infiltration and vasoac-
tivity, this did not result in a thicker smooth muscle tissue, nor
was endothelialization complete even after a 4-week implantation
(Zheng et al., 2012). In a similar study, the tripeptide cysteine–
alanine–glycine (CAG) was electrospun with PCL fibers into a
vascular graft and implanted in a Sprague-Dawley rat carotid
artery model. Kuwabara et al. previously noted that the CAG
tripeptide improved endothelialization, while it retarded smooth
muscle cell proliferation. Upon excision at 1, 2, and 4 weeks, the
authors reported improved endothelialization at all time points
and virtually complete endothelialization had occurred within
2 weeks. The presence of vWf was demonstrated at 1 week, while
the production of endothelial nitric oxide synthase (eNOS) was
detected as early as 1 week, demonstrating functional endothe-
lium. The authors also demonstrated reduced SMαA expression
at 6 weeks in the CAG-modified PCL graft, suggesting a potential
to reduce intimal hyperplasia (Kuwabara et al., 2012); however,
SMαA is a contractile phenotype marker protein and may not give
a true representation of SMC proliferation.
Although these studies investigated the ability of PCL-modified
vascular grafts to either improve patency, endothelialization, or
SMC infiltration, only the study by Wang et al. fully examined
neovascularization in vivo. Matsumura et al. had previously engi-
neered a vascular graft consisting of polyglycolide knitted fibers
and an l-lactide and ε-caprolactone copolymer sponge reinforced
with glycolide and ε-caprolactone copolymer monofilaments, but
only recently applied the biodegradable scaffold as a cell-free graft
in a canine inferior vena cava (IVC) model. Immunohistological
studies revealed endothelialization (factor VIII-positive) and SMC
proliferation (SMαA) in the TEVG at 1 and 2.5 months with elas-
tic and collagenous fibers also observed at 24 months. The authors
reported no significant differences in the hydroxyproline, elastin,
and calcium contents between the vascular graft and the native
IVC up to 24 months follow-up. Moreover, the elastic modulus
of the graft reached that of the native IVC at 2.5 months and
continued to mirror the IVC up to 24 months following implan-
tation (Matsumura et al., 2012). In a follow-up study, the authors
examined their vascular graft in a canine pulmonary artery model.
Again, they reported no significant differences in hydroxyproline
and elastin content between the left pulmonary artery and the
TEVG; however, significant calcification was observed with the
TEVG at 12 months. Although the authors noted a lack of stenosis
and thrombosis in the vasculature of any of the animals, the tubu-
lar scaffolds were 8 mm in diameter (Matsumura et al., 2013) and
may not replicate the hemodynamics of a small-diameter blood
vessel.
In another study examining neovascularization, Wang and col-
leagues implanted a poly(glycerol sebacate) (PGS) vascular graft
supported with an outer PCL sheath in the abdominal aorta of
Lewis rats. The sheath was electrospun around the tubular PGS
graft to strengthen the graft, allowing it to be sutured in place, while
preventing blood loss through the highly porous PGS network.
The authors selected PGS because it is elastomeric, allowing for
effective transduction of mechanical stimulation, while degrading
rapidly in vivo, hence minimizing the host response to a for-
eign body. At 3 months, the authors observed significant SMC
infiltration into the remodeled graft wall; however, SMαA expres-
sion was localized away from the luminal surface as shown in
Figure 3 (Wu et al., 2012). The authors also demonstrated signif-
icant ECM production at 90 days. Verhoeff ’s, Masson’s trichrome
and safranin O staining revealed the presence of elastin, collagen,
and glycosaminoglycans in the neoartery, nearing the ECM pro-
tein content of the native aorta, as shown in Figure 4 (Wu et al.,
2012). The considerable ECM protein content also had a signif-
icant impact on the mechanical properties. The neoartery was
tough yet compliant with a burst pressure approaching that of the
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FIGURE 3 | Smooth muscle cell infiltration and organization at 14 days.
(A) SMC distribution (SMαA, green) within the remodeled graft wall. The
tissue was split longitudinally, half of which is shown. Native aorta is on the
right; its border with the graft is indicated by the dashed line; scale bar,
500µm. L, lumen. (B) Magnified view of the mid-graft shows distribution of
both SMαA-positive (green) and SMαA-negative cells. Nuclei counterstained
by DAPI (blue); scale bar, 250µm. (C) Further magnification of the mid-graft to
view the complicated SMC distribution (SMαA, green); scale bar, 50µm.
(D) Distribution of endothelial cells (vWf, red) and smooth muscle cells
(SMαA, green) in the graft wall. Immunofluorescence images merged with
the bright-field image (darkened to not overwhelm the fluorescence images).
Dark spots (*) in the bright-field image might be residual graft material; scale
bar, 100µm. Adapted by permission from Macmillan Publishers Ltd. [Nature
Medicine] (Wu et al., 2012), copyright (2012).
FIGURE 4 | ECM organization and quantification at 90 days. (A) Verhoeff’s,
Masson’s trichrome, and safranin O staining show elastin (black), collagen
(blue), and glycosaminoglycansin (red), respectively. Immunofluorescence
shows distribution of elastin (red), collagen I (green), and collagen III (red).
Top: day 90 explant; bottom: native aorta. Scale bars, 50µm.
(B) Quantification of elastin (n= 4) and total collagen (n=4). Data represent
mean±SD. Adapted by permission from Macmillan Publishers Ltd.: (Nature
Medicine) (Wu et al., 2012), copyright (2012).
aorta and greater than the saphenous vein. Given the promising
results, future studies with large animals more representative of
the human vasculature are proposed.
Another material garnering attention as a vascular biomaterial
is the elastomeric poly(ester urethane)urea (PEUU) derived from
PCL diol, 1,4-diisocyanatobutane and putrescine in part due to
its mechanical properties, as it has a burst pressure strength and
suture retention strength approaching that of the ITA (Nieponice
et al., 2008). Further to their original study, Vorp, Wagner, and
colleagues have covalently attached MPC to the luminal surface of
electrospun PEUU conduits to impart anti-thrombogenicity. The
vascular grafts were then implanted in the abdominal aorta of rats
and examined upon sacrifice at 4, 8, 12, and 24 weeks. The authors
demonstrated a significant reduction in platelet adhesion in the
PMA-conjugated PEUU grafts, with a corresponding patency rate
of 92% compared to just 40% in the uncoated controls at 8 weeks.
In the occluded grafts, 90% were attributed to acute thrombo-
sis, while the remaining 10% failed due to intimal hyperplasia.
The PMA-immobilized PEUU grafts also yielded aligned collagen
and elastin fibers, both necessary precursors in neovascularization.
Moreover, the authors also demonstrated an intact endothelium
as evidenced by the continuity in vWf immunostaining between
the native aorta and the electrospun PEUU graft. The authors
also reported significant changes to the dynamic compliance and
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ultimate tensile strength of the functionalized PEUU grafts upon
excision. An initial increase in the dynamic compliance and con-
comitant decrease in ultimate tensile strength was observed at
4 weeks and believed to be the result of acute degradation of the
nodes of the electrospun fibers (Soletti et al., 2011).
Although the synthetic grafts may be easier to handle, suture,
scale up, and sterilize, while yielding more reproducible proper-
ties, some researchers believe that the high modulus and tensile
strength exhibited by fibroin, a component of spider silk, is equally
viable as a vascular scaffold material. Catteneo et al. electrospun
fibroin into 1.5 mm diameter tubular grafts that were implanted
in the abdominal aorta of Lewis rats in end-to-end anastomoses.
Upon explantation at 7 days, the constructs were infiltrated with
SMCs and lined with ECs as evidenced by the immunostaining
of SMαA and vWf, respectively. The authors also reported the
presence of elastin at 7 days, which by volume density, was approx-
imately 50% of native vessels. Despite the evidence of complete
endothelialization, the graft was only 1.5 cm in length (Cattaneo
et al., 2013). In a similar study, Lovett et al. gel spun aqueous
fibroin solutions to yield 2 cm silk tubular scaffolds and implanted
them in the abdominal aorta of Sprague-Dawley rats. Silk fibroin
(SF) grafts remained patent up to 4 weeks implantation, while
acute thrombosis in all PTFE constructs was observed in 24 h.
The recruitment of vascular cells from the adjacent native aorta
resulted in a medial smooth muscle layer and complete endothe-
lialization as confirmed by SMαA and factor VIII staining. Further
to the in vivo studies, the hemocompatibility of the SF grafts
were also studied in vitro. A reduction in thrombin and fibrino-
gen adsorption was observed compared to PTFE and although an
increase in platelet adhesion was seen from incubation of platelet-
rich plasma on SF films, the platelets were deemed non-activated
by their non-spreading morphology (Lovett et al., 2010). In a
complementary study, Yagi et al. prepared three kinds of knitted
double-raschel silk fiber grafts coated with crosslinked SF again
with an internal diameter of 1.5 mm, but with a length of 7 cm.
The grafts were also implanted in the abdominal aorta of Sprague-
Dawley rats. Upon excision at 8 weeks, gross observation of the
vascular constructs revealed patency of the most elastic and flex-
ible SF tubular graft tested, attributed to a reduction in intimal
hyperplasia. Immunohistological studies revealed SMC infiltra-
tion, resulting in smooth muscle tissue thickness similar to that of
the native rat aorta; however, complete endothelialization was not
achieved, in particular at the midpoint of the vascular graft follow-
ing 8 weeks implantation (Yagi et al., 2011). Given that incomplete
endothelialization was observed, along with growing smooth mus-
cle tissue, longer studies are necessary to ensure intimal hyperplasia
does not result in occlusion of the vascular grafts.
Attempts to minimize intimal hyperplasia from SF scaffolds
have been explored through the incorporation of heparin. Zhu
et al. prepared heparin-loaded, porous scaffolds through a mod-
ified freeze-drying approach, which permitted their fabrication
into tubular grafts. The authors demonstrated near complete
release of heparin within 3 days corresponding to a reduction in
SMC metabolic activity in vitro at 4 and 7 days. The ability of
the SF scaffolds to facilitate tissue integration in vivo was eval-
uated upon excision of subcutaneously implanted tubular grafts
in Sprague-Dawley rats. At 2 weeks, H&E staining revealed initial
tissue integration in the heparin-loaded grafts as evidenced by an
increased number of capillaries; however, at 4 weeks, the number
of capillaries decreased suggesting potential resorption of the de
novo blood vessels. Although SMC metabolic activity was retarded
at 4 and 7 days following the rapid release of heparin, there was
no statistical difference in metabolic activity at 14 days (Zhu et al.,
2014), suggesting a slower release profile or covalent attachment of
heparin may be needed to prevent long-term intimal hyperplasia
and ultimately graft occlusion.
Despite some promising results from foreign biomaterials,
other researchers have proposed that clinical success will incorpo-
rate all fundamental features of the vascular wall. Kumar et al. have
recently incorporated both fibrillar collagen type 1 and an elastin-
like polypeptide as a vascular graft. Collagen fibrils were prepared
from monomeric type 1 collagen extracted from rat tail tendon
before the ELP was coated on the surface of the collagen and
rolled to generate a luminal ELP layer on multiple fibrillar colla-
gen layers. Initial studies revealed reduced platelet adhesion in the
ELP-coated vascular graft when compared to the uncoated colla-
gen graft control. Histologically, the 2-week rat aorta interposition
study revealed little neointima formation, and continuous vWf
staining indicative of an intact endothelium. Despite the promis-
ing short-term in vivo data, the burst pressure strength and suture
retention strength still remain a fraction of that of the ITA (Kumar
et al., 2013).
In effort to improve the mechanical properties of a vascu-
lar graft yet still incorporate the fundamental features of the
vascular wall, research has focused on decellularized arterial con-
duits, which have demonstrated similar burst pressure strength,
suture retention strength, and compliance to native blood vessels
(Wilshaw et al., 2012; Sheridan et al., 2013; Xiong et al., 2013).
Recently, Hwang et al. harvested abdominal aorta from Sprague-
Dawley rats, which were evaluated as infrarenal allografts. The
decellularized implants appeared thinner with the elastic fibers
of the medial layer exhibiting less undulation when compared to
the native aorta. Following 8 weeks implantation, intimal thick-
ening due to increased collagen fibers and SMαA-positive cells
was observed. Although vWf staining revealed the presence of
endothelial-like cells on the luminal surface of the implanted
grafts, the expression was noticeably less than the native aorta
(Hwang et al., 2011). In a related study, Akhyari and co-workers
harvested rat aortae, which the authors decellularized and coated
with fibronectin. The coated vessels were implanted systemically
in Wistar rats for up to 8 weeks. Explanted fibronectin-coated
grafts exhibited improved endothelialization and medial recellu-
larization compared to uncoated controls. Despite the acceleration
in endothelial cell recruitment, a concomitant increase in local
hyperplasia was still observed (Assmann et al., 2013).
Similarly, Niklason and colleagues harvested human aortae
and then decellularized the constructs to produce human tissue-
engineered vessels (hTEV). The decellularized hTEVs exhibited
burst strength pressures similar to the saphenous vein, yet still infe-
rior to the native ITA. The grafts were implanted in an end-to-end
anastomoses in the abdominal aorta of female nude mice. Upon
excision of the grafts at 6 weeks, there was evidence of neointima
and neotissue formation on the decellularized grafts. Although
cells did not fully infiltrate the decellularized graft, both elastin
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and SMCs were prevalent. In addition, vWf staining demonstrated
the recruitment of ECs to the luminal surface of the vascular graft.
The authors acknowledge that larger animal studies are needed
and that these studies also need to examine the potential for late
stage stenosis following neotissue or neointima formation (Quint
et al., 2012).
TISSUE ENGINEERING OF VASCULAR GRAFTS IN VITRO
While some researchers have adopted the approach of in vivo tis-
sue engineering, where cells are recruited into the biodegradable
scaffold from adjacent tissue, others propose that seeded cells serve
as the “building blocks of neotissue.” In this regard, there are two
unique approaches to enhance tissue regeneration and remod-
eling: cell sheet self-assembly and cell sodding of biodegradable
scaffolds.
Cell sheet tissue engineering
The first tissue-engineered vascular graft (TEVG) prepared wholly
from cultured human cells was developed by L’Heureux et al.
(L’Heureux et al., 1993). Vascular SMCs obtained from umbil-
ical veins and fibroblasts from human skin were cultured for
30 days with ascorbic acid to produce a cohesive cellular sheet
with an associated ECM. The SMC layers were first peeled from
the culture dish and enclosed around a tubular support to pro-
duce concentric sheet layers that mimic the media of the vessel.
A secondary sheet of fibroblasts was then wrapped around the
medial layers to emulate the adventitia. After an 8-week mat-
uration period in a bioreactor, the perforated tubular mandrel
was removed and luminal endothelial cell seeding was performed.
The authors reported expression of vWf and strong inhibition
of platelet adhesion in vitro from a coherent endothelium. The
three-layered organization of the TEVG included both collagen
and elastin, yielding a burst strength of over 2000 mm Hg, which is
similar to that of human vessels. In a 7-day interpositional femoral
artery graft in mongrel dogs, the authors reported patency in three
of six animals, where occlusion from acute thrombosis resulted
from non-endothelialized vascular grafts (L’Heureux et al., 1998).
Subsequent in vivo studies evaluated the tissue-engineered blood
vessels (TEBVs) longer-term, where the authors opted to implant
the TEBV as interpositional abdominal grafts in immunodeficient
rats. Of the patent grafts explanted between 3 and 8 months, graft-
tissue integration was reported along with a smooth endothelium
with no observable change in the diameter of the graft. Moreover,
SMαA-positive cells infiltrated the media and were intertwined
with collagen and elastin fibers. But to better mimic the biome-
chanical environment, the self-assembled TEBV was also applied as
an interpositional arterial graft in immunosuppressed cynomolgus
macaques. The explanted grafts were all patent (n= 1 at 6 weeks,
n= 2 at 8 weeks) and mirrored those previously excised from nude
rats including having a smooth endothelium, SMαA-positive cell
recruitment, intact anastomoses with neither luminal narrowing
nor aneurysm formation (L’Heureux et al., 2006).
Following the encouraging in vivo studies, L’Heureux and col-
leagues set out to assess the clinical relevance of TEBVs prepared
from an age- and risk-appropriate patient population by com-
paring the burst pressure, suture retention strength, and com-
pliance of the self-assembled engineered grafts to native blood
vessels. The authors demonstrated similar burst pressure and
suture retention strengths between the internal thoracic arteries
and small-diameter TEBVs (2.4 mm diameter). Although initial
compliance of the TEBVs is lower than the native ITA, at 6 months
post-implantation, the compliance approached that of the native
ITA due to the development of a functional smooth muscle cell
media (Konig et al., 2009). Despite the promising results, vascu-
lar tissue maturation using the sheet-based technology requires at
least 28 weeks, which would preclude it from urgent clinical use
(L’Heureux et al., 2006; Konig et al., 2009).
Recent work using the cell sheet technology has focused on
improved neovascularization through in vitro pre-vascularization.
Okano and colleagues developed a five-layered construct where
human umbilical vein endothelial cells (HUVECs) were seeded
between myoblast sheets. Upon 4 days culture in vitro, capillary-
like structures were partially formed and then implanted into dor-
sal subcutaneous tissue of nude rats. At 1 week post-implantation,
the capillary-like structures joined the host’s blood vessels creat-
ing microvessels, which also contained red blood cells (Sasagawa
et al., 2010). In a more exhaustive study, Sekine et al. devel-
oped three-dimensional (3D) tissue with perfusable blood vessels
in vitro. The authors isolated cardiac cells from the ventricles of
Sprague-Dawley and Lewis neonatal rats (Sekine et al., 2013).
Cardiac cells were co-cultured with ECs and seeded on temper-
ature sensitive culture dishes for ease of cell sheet recovery. Upon
stacking of the cardiac sheets, they were overlaid on a vascular
bed from resected femoral tissue containing a connectable artery
and vein as shown in Figure 5A. Media was supplied through
the femoral artery (Figure 5B) and perfused through the vascu-
lar bed. The authors demonstrated that in the absence of ECs,
no tubular structure was observed in the trilayered cell sheet, and
that fibroblast growth factor-2 (FGF-2) was necessary to ensure
media diffusion from the vascular bed to the cell sheet construct.
In combination, the co-culture of ECs in the cardiac sheets enabled
the formation of new blood vessels, while the FGF-2 facilitated
the connection of these new blood vessels with the vasculature
of the underlying femoral tissue. The three-dimensional tissue-
engineered construct remained viable in vitro via media supplied
through the newly formed vessels. The functional tissue was then
implanted in nude mice where the femoral artery and vein of the
construct were reconnected to the carotid artery and the jugular
vein, respectively. A cell sheet construct without a vascular bed
and a vascular graft without blood vessel anastomoses served as
controls. At 2 weeks, the rats were euthanized and tissue viability
was significantly greater in the vascular graft with the blood vessel
anastomoses. Moreover, immunostaining of CD31 and calponin
highlighted a uniform distribution of blood vessels in the cell sheet
construct (Sekine et al., 2013).
Cell sodding of biodegradable scaffolds
Weinberg and Bell were the first to prepare a biological vascular
graft, which incorporated bovine SMCs, ECs, and fibroblasts into
a collagen gel. The authors initially prepared the tunica media
by embedding SMCs and culture media with collagen that gelled
around a central mandrel within minutes at 37°C. At 1 week, a
Dacron mesh sleeve was placed over the collagen gel to provide
additional mechanical support prior to the addition of adventitial
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FIGURE 5 | In vitro engineering of functional 3D tissue with perfusable
blood vessels. (A) To engineer cell sheet constructs with perfusable blood
vessels, EC co-cultured cardiac cell sheets are stacked, and then overlaid on a
vascular bed in vitro. After appropriate perfusion using a bioreactor, the
co-cultured ECs formed new blood vessels and connected with the blood
vessels that originated from the vascular bed. Finally, the cell sheet
constructs survive via the media supplied through the new vessels formed
in vitro. (B) The engineered constructs are perfused in a custom-made
bioreactor. Adapted by permission from Macmillan Publishers Ltd.: (Nature
Medicine) (Sekine et al., 2013), copyright (2013).
fibroblasts. Upon removal of the mandrel, ECs were suspended in
media and injected into the lumen of the vessel and rotated for a
week to ensure uniform distribution. A virtually confluent mono-
layer of ECs produced vWf and prostacyclin, a known inhibitor of
platelet aggregation. Despite the presence of a functional endothe-
lium, burst strengths from the engineered vascular grafts could
only be optimized to 323± 31 mm Hg. The lack of burst strength
was attributed to a number of factors including lack of elastin,
low density of both SMCs and collagen as well as the longitudinal
orientation of the collagen fibers and SMCs when compared to
native blood vessels (Weinberg and Bell, 1986). Several attempts
to improve the mechanical properties of collagen gels have been
explored including crosslinking with glutaraldehyde, lysyl oxidase
(Elbjeirami et al., 2003), and transglutaminase (Orban et al., 2004),
yet no collagen construct approached the mechanical strength of
native blood vessels.
Following the initial work with collagen gels, further efforts
to improve the mechanical properties of cell sodded biodegrad-
able scaffolds have been explored using bioreactors to replicate the
cyclic hemodynamic loading experienced in vivo. Niklason et al.
initially demonstrated that SMCs when cultured dynamically for
8 weeks on tubular degradable polyglycolic acid (PGA) meshes
yielded densely packed layers of SMCs. The engineered vessels
exhibited rupture strengths in excess of 2000 mm Hg (Niklason
et al., 1999), exceeding the burst pressure of the saphenous vein
(L’Heureux et al., 1998). Subsequent studies have also revealed
improved smooth muscle cell proliferation (Park et al., 2012) and
mechanical properties in dynamic culture conditions (Wang et al.,
2010; Song et al., 2011; Mun et al., 2013). In addition, the studies by
Kim and colleagues revealed increased collagen (Mun et al., 2013)
and elastin deposition under dynamic culture in their collagen
coated poly(l-lactide-co-ε-caprolactone) tubular grafts; however,
upon continued dynamic culture, loss of seeded HUVECs was
observed (Park et al., 2012). Although dynamic culture of SMCs
has demonstrated improved cell proliferation, ECM production,
and cell orientation may be influenced by cell source, scaffold,
and bioreactor design. Wang et al. demonstrated increased col-
lagen deposition from adipose stem cell-derived SMCs in PGA
meshes upon pulsatile flow, yet showed no effect on elastin synthe-
sis (Wang et al.,2010). Three week dynamic cultures on elastomeric
PGS tubular constructs resulted in increased levels of both insolu-
ble collagen and elastin synthesis, which the authors attributed to
improved mechanical transduction of the cyclic radial distension
from the bioreactor to the SMCs (Lee and Wang, 2011). Kaplan
and colleagues observed smooth muscle cell orientation parallel
to fluid flow on silk-based scaffolds (Zhang et al., 2009), while
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both Lee and Wang and Ratcliffe reported smooth muscle cell ori-
entation perpendicular to fluid flow on synthetic polymer based
scaffolds, similar to native vessels (Lee and Wang, 2011; Ratcliffe,
2000). Despite the conflicting data, realizing that mechanical prop-
erties mimicking those of native blood vessels can be imparted to a
tubular scaffold through the dynamic loading of a perfusion biore-
actor facilitates the development of a tissue-engineered vascular
graft.
Role of sodded cells. Although evidence of improved cell infil-
tration and orientation into vascular scaffolds during in vitro
maturation further reinforced the adage that seeded cells served
as the building blocks of neotissue, this behavior has not fully
replicated in vivo. In 2008, Roh et al. developed a small (<1 mm)
diameter vascular graft for use in a mouse model. The scaffolds
were prepared by rolling non-woven polyester sheets of either
PGA or poly(l-lactic acid) PLLA around either 21 or 22 gauge
needles and then sealing them with a copolymer solution of
poly(ε-caprolactone-co-l-lactide) [P(CL/LA)]. The scaffolds had
excellent mechanical properties with burst pressures in excess of
the venous burst pressures and greater suture retention strength
than both venous and arterial blood vessels. The intrinsic elastic-
ity was measured as a function of Young’s modulus, and despite
the vascular scaffolds being stiffer than native vessels, the scaffolds
were more elastic than ePTFE prosthetic grafts (Roh et al., 2008).
In a follow-up study, the PGA-P(CL/LA) scaffolds were seeded
with human bone marrow mononuclear cells (hBM-MNCs) and
implanted as IVC interposition grafts in immunodeficient mice.
The authors investigated the premise that stem cells in the BM-
MNC population differentiate into vascular SMCs and ECs of
the neovessel. All hBM-MNC seeded vascular grafts remained
patent throughout the 24-week study. Upon study completion,
mature vasculature was also evident including the presence of
a confluent endothelium and a sub-endothelium SMC medial
layer. Despite the degradation of the scaffold and its replace-
ment with collagen fibrils, no elastin was detected in the TEVGs.
Upon excision of the implants throughout the course of the 24-
week study, the authors tested the grafts for hBM-MNC surface
antigens. After 1 week post-implantation, Roh et al. confirmed
the absence of human RNA from the seeded hBM-MNCs in
the TEVGs using quantitative real time polymerase chain reac-
tion (qPCR). Although the hBM-MNCs were not retained or
incorporated into the tissue-engineered vascular graft as differ-
entiated cells, the presence of mouse SMCs and ECs following
mouse monocyte recruitment suggested that the TEVGs appear to
undergo inflammation-induced vascular remodeling. Despite the
ultimate loss of hBM-MNCs, their secretion of the cytokine CCL2
increased monocyte recruitment suggesting that the hBM-MNCs
were adopting a paracrine mechanism in neovessel development
(Roh et al., 2010).
The postulation that seeded cells participate in neovessel for-
mation via paracrine signaling was further evaluated. Breuer and
his colleagues tested the effect of BM-MNCs on the TEVGs
implanted in macrophage-depleted mice. The authors demon-
strated that macrophages (differentiated monocytes) are critical
for TEVG patency as the complete inhibition of macrophage
infiltration prevented neotissue formation. Conversely, excessive
macrophage infiltration was observed in the unseeded grafts,
which resulted in neointimal hyperplasia, and ultimately a stenotic
or occluded graft. In fact, early stenosis occurred in 80% of
unseeded TEVGs, but only 20% of seeded TEVGs in an IVC
interposition graft. Consequently, patency was improved in the
cell-seeded grafts when compared to unseeded controls (Hibino
et al., 2011b).
In spite of hBM-MNC loss upon implantation of the TEVG in
immunodeficient mice, the patency of all grafts at 24 weeks with
a well-developed vasculature including a coherent endothelium
and smooth muscle cell medial layer suggested that the neoves-
sel was composed entirely of host cells. To ensure that xenograft
transplantation rejection was not responsible for the loss of hBM-
MNCs in the immunodeficient mice, syngeneic BM-MNCs were
also seeded on TEVGs, and implanted in mice. Again the authors
observed almost complete replacement of the BM-MNCs with
macrophages, with only 0.02% of the originally seeded cells still
present at 14 days. Moreover, the BM-MNCs were not a significant
source of either the ECs or SMCs of the neovessel. The vascular
cells forming 93% of proximal neotissue were in fact recruited
from the adjacent vessel wall (Hibino et al., 2011a).
While seeded cells may not be incorporated into neotis-
sue, extensive research demonstrates the improved patency of
TEVGs seeded with cells. Mo and colleagues investigated pre-
endothelialized vascular scaffolds in a canine bilateral femoral
artery implant model. An autologous endothelial cell suspension
was fed through tubular poly(l-lactic acid-co-ε-caprolactone)
[P(LLA-CL)] scaffolds and rotated on roller mixer for 7 days
to ensure a uniform distribution of ECs prior to implantation.
Graft patency was monitored using digital subtraction angiogra-
phy and color Doppler flow imaging. As early as 1 week, three of
eight P(LLA-CL) grafts had already occluded, and at 3 months,
only one graft remained patent. Conversely, three of four pre-
endothelialized grafts remained patent at 3 months, which the
authors attributed to greater luminal monolayer coverage of
the pre-seeded grafts (Huang et al., 2013). Notwithstanding the
improved patency of the cell sodded grafts, the presence of a cell
monolayer does not in and of itself prove that the seeded cells
survived in the absence of a cell tracker. Although immunocy-
tochemical analyses were not conducted, the presence of a cell
monolayer and the patency of the vascular grafts suggest the
TEVGs were lined with autologous ECs.
In addition to a functional endothelium, patent TEVGs will
need to be supported with a medial layer of vasoactive SMCs;
however, due to their slow propagation in vitro, focus has shifted
to more rapidly proliferating stem cells or the incorporation of
progenitor cells. Much controversy has surrounded the use of
embryonic stem cells, but with the ability to harvest adult mes-
enchymal stem cells (MSCs) from bone marrow mononuclear
cells, adipose tissue, and skeletal muscle tissue, significant research
in stem cell-based tissue engineering has emerged (Krawiec and
Vorp, 2012). In addition to the MSCs, the reprograming of somatic
cells to induced pluripotent stem (iPS) cells has further expanded
the possible use of stem cells in tissue engineering (Takahashi and
Yamanaka, 2006).
Cho et al. were the first to examine differentiated bone marrow
mononuclear cells in a TEVG in a canine carotid artery model.
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Both SMαA/SMMHC-positive cells and vWf/CD31-positive cells
from the mononuclear cell fraction were cultured for 3 weeks
in vitro to obtain enough cells for seeding. First, SMαA/SMMHC-
positive cells were uniformly seeded onto small-diameter decellu-
larized canine carotid arteries, followed 2 h later by the vWf/CD31-
positive cells, which were seeded onto the luminal surface of the
scaffolds and cultured for 1 week prior to implantation in an end-
to-end anastomoses of the carotid artery. Explanted grafts showed
elements of an intact endothelium with well-defined medial and
adventitial layers. Moreover, the TEVGs remained patent up to
8 weeks post-implantation, while unseeded grafts occluded within
2 weeks. The explanted grafts also revealed the presence of the fluo-
rescently labeled BM-MNCs up to 8 weeks, indicating that some of
the BM-MNCs actively participated in the vascular tissue regener-
ation (Cho et al.,2005). In a follow-up study, the authors seeded the
canine BM-MNCs onto a poly(lactide-co-ε-caprolactone) scaffold
supported by PGA fibers. Excision of the TEVGs at 8 weeks in a
canine abdominal aorta model revealed that the TEVG underwent
significant remodeling with a structure similar to that of the native
aorta (Lim et al., 2008). Similarly, Zhou et al. decellularized a har-
vested canine carotid artery for examination as a TEVG. The decel-
lularized vessel was coated with heparin, seeded with endothelial
progenitor cells (EPCs) from peripheral blood, and matured in
a bioreactor for 1 week prior to re-implantation. At 3 months,
histological analyses revealed complete endothelialization in the
EPC-seeded TEVG compared to unseeded decellularized vessels
(DVs). In addition, immunofluorescence confirmed the presence
of seeded cells lining the luminal surface of the TEVG. Significant
reduction in hyperplastic neointima was also observed resulting
in increased graft patency (95 versus 60% for the TEVGs and DVs,
respectively) at 3 months (Zhou et al., 2012). The incorporation
of the bone marrow mononuclear cells into the remodeled vascu-
lar tissue contradicts the observations of Breuer and colleagues;
however, the behavior of MSCs is directly related to their perivas-
cular environment (da Silva Meirelles et al., 2006) and may differ
between humans and dogs.
Notwithstanding the in vivo remodeling following the TEVG
implantation, the time needed for differentiation of the bone mar-
row mononuclear cells would hinder its use as an off-the-shelf
vascular graft. The seeding of non-differentiated BM-MNCs onto
a biodegradable vascular scaffold was first reported by Matsumura
et al. The BM-MNCs were also seeded on a poly(lactide-co-ε-
caprolactone) scaffold, but supported by poly(l-lactide) fibers and
then implanted in the IVC of beagles. The explanted grafts were
analyzed immunohistochemically at 3 h and again at 2, 4, and
8 weeks post-implantation. Stenosis was not observed in any of
the TEVGs while patency was maintained up to 2 years follow-
ing implantation. Immunohistochemistry revealed that seeded
BM-MNCs initially expressed endothelial cell lineage markers
including CD34, CD31, Flk-1, and Tie-2. Following proliferation
and differentiation of the bone marrow mononuclear cells, expres-
sion of endothelial cell markers CD146, factor VIII, and CD31, as
well as smooth muscle cell markers SMαA, embryonic SMMHC
(SMemb), and SMMHC isoforms SM1 and SM2 were observed
implying the differentiation of the BM-MNCs into mature vascu-
lar cells in vivo (Matsumura et al., 2003). Despite the promising
remodeling in vivo, the inner diameter of the degradable grafts
selected for these studies were 10 and 8 mm, respectively, approx-
imately twice the diameter of any healthy male coronary artery
(Dodge et al., 1992).
More recently Wu et al. compared four types of scaffolds (inner
diameter of 5 mm) to evaluate their ability to direct BM-MNC
differentiation in vitro and promote vascular tissue formation.
Rat BM-MNCs were seeded on PLGA, PGS, platelet-poor plasma-
coated PGS, and plasma-coated PGS supplemented with platelets.
The authors examined the impact of platelet adhesion on differ-
entiation of bone marrow mononuclear cells, as platelets have
been identified in recruiting circulating endothelial progenitor
cells through paracrine release of stem cell-derived factor-α and
vascular endothelial growth factor (VEGF). The expression of
calponin-I and SMαA and deposition of collagen and elastin from
cells cultured on PGS scaffolds suggested smooth muscle differ-
entiation. Although increased cell proliferation was observed with
platelet supplementation, and hence ECM secretion, the authors
did not report the impact of platelets on the differentiation of
stem cells into mature ECs. vWf immunohistochemistry revealed
the presence of the blood glycoprotein in platelets (Wu et al., 2011),
but its absence at the luminal surface, as expected in ECs, perhaps
suggests that the platelets did not actively recruit the EPCs from
BM-MNCs, or that the BM-MNCs preferentially differentiated
into SMCs.
Although, Wu et al. did not report the presence of ECs or
their markers, bone marrow mesenchymal stems cells (MSCs),
a small portion of the mononuclear cell fraction, have been suc-
cessfully differentiated into ECs in vitro (Dong et al., 2009; Moby
et al., 2011). The controlled in vitro differentiation of bone mar-
row MSCs to smooth muscle-like and endothelial-like cells can be
achieved through supplement manipulation of the culture media
(Zhao et al., 2010). Decellularized ovine carotid artery grafts were
seeded with the autologous cells and implanted as interposition
grafts. The seeded grafts remained patent for up to 5 months, while
the unseeded controls occluded within 2 weeks. The presence of an
endothelium and smooth muscle within the TEVG was observed
at both 2 and 5 months as demonstrated through immunohisto-
chemical staining of vWf and SMαA, respectively. MSCs labeled
with PKH26, a cell membrane bound fluorescent dye, was detected
in the luminal side of the tunica media at 2 months, but not at
5 months, suggesting repopulation of the vascular graft (Zhao
et al., 2010). Similar observations of improved patency have been
reported with bone marrow MSC- and EPC-seeded PLLA-PGA
scaffolds in a mouse carotid artery model. The authors also labeled
the bone marrow MSCs with green fluorescent protein (GFP) and
noted a reduction in GFP expression at 35 days when compared to
7 days, further supporting the premise of graft repopulation with
host cells (Hjortnaes et al., 2010). Hashi et al. seeded bone marrow
MSCs onto PLLA scaffolds and implanted them into the common
carotid artery of rats for 60 days. Well-distributed SMCs within
the TEVG indicated strong MSC infiltration and differentiation.
Neointimal thickening was only observed in the unseeded con-
trols. Staining for CD31 revealed not only luminal coverage of the
TEVG with ECs, but their presence in the outer layer of the graft
suggesting microvessel formation in the surrounding tissue. The
authors also reported that explanted grafts at 60 days showed sig-
nificant collagen deposition; however, only the MSC-seeded grafts
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exhibited a sub-luminal elastic lamina layer. Finally, the authors
also showed that as early as 7 days, most cells were again recruited
from the host due to the absence of human antigen nuclear mitotic
apparatus staining in the seeded grafts (Hashi et al., 2007).
The accumulating evidence that cells sodded on vascular grafts
significantly improve patency rates when compared to unseeded
grafts, yet fail to integrate in neotissue formation, further validates
the postulation that seeded cells supplement the host’s innate heal-
ing process through paracrine signaling. Specifically, Breuer and
colleagues believe that upon implantation of the bone marrow
mononuclear cell-seeded tissue engineering graft, the BM-MNCs
secrete chemokines such as CCL2, which is known to attract
circulating monocytes. Following the differentiation of mono-
cytes to macrophages, platelet derived growth factor (PDGF), and
VEGF are released promoting infiltration of adjacent endothelial
and SMCs, which together with the macrophages and fibrob-
lasts begin secreting the ECM. During scaffold degradation, ECM
remodeling continues with a concomitant exodus of macrophages
yielding a completely autologous neovessel (Weber et al., 2011;
Kurobe et al., 2012).
CONCLUSION
With the increasing rate of CAD coupled with the lack of autol-
ogous grafts due to repeat surgery or venous disease and the lack
of growth potential in synthetic prostheses, the development of
a tissue-engineered vascular graft remains an integral part of the
coronary revascularization strategy. Although greater patency of
TEVGs is being observed in animal models following cell sodding,
the improved patency is attributed to paracrine signaling, sug-
gesting the delivery of signaling molecules, potentially in lieu of
a patient’s own cells may facilitate the development of a readily
available “off-the-shelf” vascular graft expediting its translation to
the clinic.
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